Abstract
The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.
Original language | English |
---|---|
Pages (from-to) | 517-24 |
Number of pages | 8 |
Journal | Drug Discovery Today |
Volume | 9 |
Issue number | 12 |
DOIs | |
Publication status | Published - 15 Jun 2004 |
Keywords
- Adjuvants, Immunologic
- Animals
- Antibodies, Monoclonal
- Arthritis, Rheumatoid
- Comparative Study
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Encephalomyelitis, Autoimmune, Experimental
- Immune System Diseases
- Immunotherapy
- Journal Article
- Multiple Sclerosis
- Organ Transplantation
- Review